Skip to Content

What type of drug is Takhzyro?

Medically reviewed by Last updated on Sep 11, 2018.

Official Answer


Takhzyro is a human plasma kallikrein inhibitor (blocks kallikrein). Plasma kallikrein regulates bradykinin production, a chemical that leads to inflammation (swelling).

Takhzyro (lanadelumab-flyo) is the first monoclonal antibody approved in the U.S. to prevent hereditary angioedema (HAE) types I and II in patients 12 years and older.

Takhzyro is given as a self-administered, subcutaneous (under the skin) injection every 2 weeks. Kalbitor (ecallantide), from Shire, is also an approved inhibitor of plasma kallikrein but is approved to treat (not prevent) attacks of hereditary angioedema in patients 12 years and older.

What is hereditary angioedema (HAE)?
Hereditary angioedema (HAE) is a rare genetic condition that occurs in people with low levels of certain proteins (C1-INH and C4) which triggers excessive activation of the complement pathway. HAE leads to severe, sudden swelling in the body caused by fluid that collects in deep layers of the skin, and may affect the stomach, limbs, face and throat.

Related Medical Questions

Drug Information

Related Support Groups